Aktienanalyse zu Phibro Animal Health Corp (PAHC)PAHCPhibro Animal Health Corp

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phibro Animal Health Corp is a good buy right now due to its recent strong financial performance, with a 37% increase in adjusted net income for Q4 2026, reaching $35 million, and a projected net income for FY 2027 between $122 million and $132 million, reflecting a 27% growth expectation. The current price of $38.30 is below the analyst price target of $44, indicating a potential upside of 15%. However, the RSI is at 73.97, suggesting the stock may be overbought, which is a risk to consider.

6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.